Subject(s)
Adenoids , Microbiota , Tonsillectomy , Adenoidectomy , Humans , Hypertrophy , Palatine TonsilABSTRACT
OBJECTIVES: To explore the causes of cochlear implantation and reference function of old electrical stimulation electrode in cochlear reimplantation in children. METHODS: The causes, surgical methods and problems found during the operations of 24 cases of cochlear reimplantation in Henan Children's Hospital from June 2016 to April 2018 were analyzed. RESULTS: Twenty-three cases successfully completed the surgery of cochlear-reimplantation, and the remaining one case had approximately 1/3 of the anterior end of the residual cochlear electrode due to high resistance at the time of withdrawal of the electrodes. The causes of re-implantation were implant equipment failure (eleven cases), elevated impedance values of all electrodes after head trauma (two cases), and implant prolapse together with the electrode caused by a traffic accident (one case). CONCLUSION: The old stimulus electrode can provide an important reference to reduce the risk of operation and ensure the success of the reoperation.
Subject(s)
Cochlear Implantation , Cochlear Implants , Child , Cochlea , Electric Stimulation , Humans , Reoperation , ReplantationABSTRACT
Summary The patient was admitted with the complain about sleep snoring with suffocation last for half a year. Adenotonsillectomy was performed. Preoperative examination showed that there was no respiratory infection, or other surgical contraindications. The process of operation was successful. One day after surgery, the child developed chest pain and fever. Chest CT showed left lobar pneumonia. After Bronchoscopy and alveolar lavage and antibiotic use, the symptom was improved. General anesthesia and surgery were the cause of pneumonia. This case showed the association between lower respiratory tract infection and obstructive pathophysiological changes in the upper respiratory tract, and the possibility of complicated lobar pneumonia after adenotonsillectomy in children with OSA.î.
Subject(s)
Adenoidectomy , Pneumonia , Sleep Apnea, Obstructive , Tonsillectomy , Adenoidectomy/adverse effects , Child , Humans , Pneumonia/etiology , Sleep Apnea, Obstructive/surgery , Snoring , Tonsillectomy/adverse effectsABSTRACT
Ten patients with advanced liver cancer, primary in 5 and metastatic in the other 5, were treated with lymphokine-activated killer cells, autologous (aLAK) and/or homologous (hLAK) combined with human natural IL-2. Each course of treatment lasted 10 days. For aLAK/IL-2 treatment, white cells were collected from the patients to be treated by a cell separator on Day 4 and after 3-day culture of the mononuclear cells in vitro in the presence of IL-2 (500 units/ml), the aLAK cells (1-2 x 10(9)) were transferred back to the patient on Day 7 via the hepatic artery by selective catheterization. IL-2 (20-30 x 10(4) units) was given i.v. daily on Days 1, 2, 8, 9 and 10. For hLAK/IL-2 treatment LAK cells from healthy donors (0.5-1 x 10(9)) were administered i.v. on Days 1, 4, and 7 and IL-2 (20-30 x 10(4) units) i.v. daily on Days 2, 3, 5, 6, 8, 9, 10. Patients with primary liver cancer were all treated with aLAL/IL-2, followed by hLAK/IL-2 in 3. Patients with metastatic cancer in the liver were either treated with hLAK/IL-2 alone or in combination with aLAK/IL-2. The results of the treatment as monitored by B ultrasonography, CT scan and digital selective angiography are as follows: CR in 2 (with metastatic liver cancer), PR in 4 (3 with primary and 1 with metastatic liver cancer), MR in 2 and no response in 2. On follow-up, 7 patients survived greater than 6 months and 1 (a complete responder) for greater than 12 months. Side effects were mild with transient fever up to 38.5 degrees C and general malaise.
Subject(s)
Carcinoma/therapy , Immunotherapy, Adoptive , Interleukin-2/therapeutic use , Killer Cells, Lymphokine-Activated/physiology , Liver Neoplasms/therapy , Adult , Carcinoma/secondary , Female , Humans , Liver Neoplasms/secondary , Male , Middle Aged , Stomach Neoplasms/pathologyABSTRACT
In order to investigate the distribution and excretion of sterigmatocystin, a carcinogenic mycotoxin, radioactively labelled compound was studied in rats. The highest concentration of radioactivity in serum appeared 3 h after administration of 0.5 microCi/g bw. The half-lives of distribution and excretion were 0.51 h and 43.9 h, respectively. The radioactivity was concentrated mainly in liver, stomach, kidney, duodenum and lung and to a lesser extent in fat, muscle, testis, rectum and bone. By 48 h, 56.4% had been excreted in faeces and 20.1% in urine. Biliary excretion may be the major route of excretion of sterigmatocystin.
